<DOC>
	<DOCNO>NCT00577824</DOCNO>
	<brief_summary>This long term , placebo-controlled trial intend assess efficacy safety exenatide , dosed twice day , Japanese patient Type 2 Diabetes treat oral antidiabetic ( ) well control .</brief_summary>
	<brief_title>Efficacy Safety Exenatide Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic ( )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Diagnosed type 2 diabetes . Has treat sulfonylurea ( SU ) alone , SU biguanide , SU thiazolidinedione least 90 day prior study start . In patient receive SU alone , dose must within dose range maximum maintenance dose maximum approve dose . The patient concomitant use alpha glucosidase inhibitor ( acarbose , voglibose miglitol ) meglitinide derivative ( mitiglinide nateglinide ) include study , drug must discontinue study start . Have HbA1c 7.0 % 10 % study start . Have body weight &gt; =50 kg . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have participate study previously study use exenatide glucagonlike peptide1 ( GLP1 ) analog within last 90 day . Have treat exogenous insulin within 90 day study start . Have continuously treat drug directly affect gastrointestinal motility total 21 day 90 day prior study start . The combination therapy sulfonylurea , biguanide thiazolidinedione allow .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>LY2148568</keyword>
	<keyword>Byetta</keyword>
	<keyword>Lilly</keyword>
	<keyword>Amylin</keyword>
</DOC>